Our quest to develop the next generation of antibody therapeutics recognizes the inherent value in working with resourceful and like-minded partners.

By partnering to enable access to third-party technologies and antibody-based products, we facilitate development of first-in-class or best-in-class antibody therapies and work to transform the future of cancer treatment.

In addition to cancer, we may consider partnership opportunities to address any disease area where antibody-based therapies may be effective, including autoimmune conditions, inflammation, central nervous system conditions and infectious diseases.

During clinical development of our proprietary antibody products, we identify potential partners that will work with us in various ways to enable the full commercial potential of these products to be realized.